Considerations of aspirin use for the prevention of colorectal cancer (CRC) should appropriately balance the benefits and risks.
In this video, Joseph Sung, MD, PhD, of the Chinese University of Hong Kong, discusses a population-based study that examined CRC mortality and gastrointestinal bleeding in patients with a history of long-term low-dose aspirin use (6 months or greater). The study included 689,209 patients, comparing outcomes in 206,243 regular aspirin users with 482,966 non-users.
Dr. Sung presented the study (abstract 527) at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.